Clinical Trial Update: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children [Phase 3]

View source ↗

Summary

Phase 3 study evaluating catch-up regimens of the 13-valent pneumococcal conjugate vaccine in older infants and children; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2012-08-15